Polypeptides for treating and/or limiting influenza infection

摘要

The present invention provides polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier. Additionally, the present invention provides methods for treating and/or limiting an influenza infection, methods for diagnosing an influenza infection, or monitoring progression of an influenza infection, methods for identifying candidate influenza vaccines, and methods for identifying candidate compounds for treating, limiting, and/or diagnosing influenza infection.

主权项

1. A polypeptide comprising an amino acid sequence according to general formula I
R1-R2-Phe-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-X1-R17 (SEQ ID NO: 2), wherein
R1 is selected from the group consisting of Ser, Ala, Phe, His, Lys, Met, Asn, Gln, Thr, Val, Tyr, and Asp;R2 can be any amino acid;R3 is selected from the group consisting of Asp, Ala, Glu, Gly, Asn, Pro, Ser, and Tyr;R4 is selected from the group consisting of Leu and Phe;R5 can be any amino acid;R6 is selected from the group consisting of Met, Phe, His, Ile, Leu, Gln, and Thr;R7 is selected from the group consisting of Arg, Gly, Lys, Gln, and Thr;R8 is selected from the group consisting of Ile, Asn, Gln, Val, and Trp;R9 is selected from the group consisting of Met, Gly, Ile, Lys, Leu, Asn, Arg, Ser, Thr, Val, His, and Tyr;R10 is selected from the group consisting of Trp and Phe;R11 is selected from the group consisting of Ile, Phe, Ser, Thr, and Val;R12 is selected from the group consisting of Tyr, Cys, Asp, Phe, His, Asn, and Ser;R13 is selected from the group consisting of Val, Ala, Phe, Ile, Leu, Asn, Gln, Thr, and Tyr;R14 is selected from the group consisting of Phe, Glu, and Leu;R15 is selected from the group consisting of Ala, Gly, Lys, Arg, and Ser;R16 is selected from the group consisting of Phe, Cys, His, Lys, Leu, Met, Asn, Gln, Arg, Thr, Val, Trp, and Tyr.X1 is comprises the amino acid sequence Z1-Arg-Z2-Ile-Pro (SEQ ID NO: 3), wherein Z1 is Lys or Asn, and Z2 is selected from the group consisting of Lys, Pro, Gln, and Thr; andR17 is Phe or Tyr.